by Ian Ingram: Complete Post through this link…
Vowst approved for preventing recurrent C. difficile infections after antibiotics.
The FDA approved the first oral fecal microbiota productopens in a new tab or window for preventing recurrent Clostridioides difficile infections in adults, the agency announced on Wednesday.
Developed as SER-109 and given the trade name of Vowst, the therapy is indicated for patients who have already received a course of antibiotics for recurrent C. difficile infections.
SER-109 — which involves four pills taken once a day for 3 consecutive days — contains live bacteria from donor fecal matter, with the donors and stool screened for a slew of pathogens. Despite that, the agency still warns that the product carries the potential risk of transmitting infectious agents or food allergens.
